BioAge Labs (BIOA) EBITDA (2023 - 2026)

BioAge Labs (BIOA) has 4 years of EBITDA data on file, last reported at -$25.4 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 54.29% year-over-year to -$25.4 million; the trailing twelve-month figure through Mar 2026 stood at -$101.7 million (down 24.3% YoY), and the FY2025 full-year result was -$92.8 million, down 18.65% from the prior year.
• EBITDA grew to -$25.4 million in Q1 2026, from -$28.4 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$9.9 million in Q3 2023 to a low of -$28.4 million in Q4 2025.
• A 4-year average of -$20.0 million and a median of -$23.1 million in 2025 frame the typical range for EBITDA.
• Across the five-year window, EBITDA sank 150.33% in 2024 and climbed 6.51% in 2025, its largest moves.
• Tracing BIOA's EBITDA over 4 years: stood at -$13.6 million in 2023, then sank by 86.54% to -$25.4 million in 2024, then dropped by 12.07% to -$28.4 million in 2025, then advanced by 10.72% to -$25.4 million in 2026.
• Business Quant data shows BIOA's EBITDA at -$25.4 million in Q1 2026, -$28.4 million in Q4 2025, and -$23.1 million in Q3 2025.